# OnCo record paper-relativity-098-nat-med-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-relativity-098-nat-med-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-relativity-098-nat-med-2025" ;
  schema:name "Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial"@en ;
  schema:description "Published report from the RELATIVITY-098 trial registered as NCT05002569, in Nature Medicine (2025), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-relativity-098-nat-med-2025/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-025-04032-8>, <https://pubmed.ncbi.nlm.nih.gov/41109920/>, <https://europepmc.org/article/MED/41109920>, <https://clinicaltrials.gov/study/NCT05002569> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1038/s41591-025-04032-8> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Long GV, Garnett-Benson C, Dolfi S, et al." ;
  onco:trials <https://onco.cc/trials/relativity-098/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .